Adding Icaritin to standard therapy for advanced liver cancer
Part of Cancer clinical trials.
This study compares two combinations of treatments for advanced liver cancer that cannot be removed with surgery. One group gets the standard care (TACE plus immunotherapy and targeted therapy) and the other gets the same plus an extra pill called icaritin. The goal is to see if adding icaritin improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer (hepatocellular carcinoma) that cannot be removed with surgery, transplant, or ablation, but it can be treated with TACE (a procedure that blocks blood flow to the tumor).
- You have not had systemic treatment (like chemo, targeted pills, or immunotherapy) for your liver cancer before, or you had it and your cancer returned after curative surgery.
- You have at least one measurable tumor, and the total tumor burden is less than half of your liver.
- You are physically active and able to care for yourself (ECOG score 0 or 1).
- Your liver function is good (Child-Pugh A), and your blood, liver, and kidney tests are within the required ranges.
- summary
- Your expected survival is at least 3 months.
- You can swallow pills and are willing to use birth control if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests combining a natural compound (Icaritin) with standard chemotherapy (mFOLFOX) after liver cancer surgery to lower the chance of the cancer coming back. It is for patients whose cancer had certain high-risk features, like a large tumor or cancer in blood vessels.
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.